Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCND3 | P30281 | 1/20 | 0.33 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16320778 | 0.77 | ALDH1A1 (0.41) | CDK2S1PR2 | |
| SCHEMBL18916737 | 0.73 | MAPT (0.34) | PDE10A | |
| SCHEMBL15006470 | 0.71 | DPP4 (0.39) | ADORA2AADORA1SYK | |
| SCHEMBL3081863 | 0.71 | ADORA2A (0.49) | ADORA2AADORA1IRAK4 | |
| SCHEMBL18916804 | 0.70 | ADORA2A (0.39) | ADORA2AADORA1IRAK4CCNA2CDK2 | |
| Hydrochloric Acid SCHEMBL4030867 | 0.70 | ADORA2A (0.47) | ADORA2AADORA1IRAK4 | |
| Hydrochloric Acid SCHEMBL4032485 | 0.70 | ADORA2A (0.47) | ADORA2AADORA1IRAK4 | |
| SCHEMBL19182622 | 0.69 | TGFBR1 (0.33) | SYK | |
| SCHEMBL14335004 | 0.67 | IRAK4 (0.51) | ADORA2AADORA1IRAK4 | |
| SCHEMBL16003798 | 0.66 | KDM4E (0.35) | ADORA2AADORA1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190071441-A1 | PYRAZOLE DERIVATIVE MANUFACTURING METHOD | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2019-03-07 | — | — | US | disclosed |
| US-10174025-B2 | Pyrazole derivative manufacturing method | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20180099964-A1 | PYRAZOLE DERIVATIVE MANUFACTURING METHOD | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2018-04-12 | — | — | US | disclosed |
| US-9879009-B2 | Pyrazole derivative manufacturing method | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2018-01-30 | — | — | US | disclosed |
| US-20170217958-A1 | PYRAZOLE DERIVATIVE MANUFACTURING METHOD | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-3176167-A1 | PYRAZOLE DERIVATIVE MANUFACTURING METHOD | Mochida Pharmaceutical Co., Ltd. (JP) | 2017-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217958-A1 | PYRAZOLE DERIVATIVE MANUFACTURING METHOD | CYP3A7, CYP2C19, CYP3A5 | ADORA2A 2558/4885ADORA1 2205/4885IRAK4 1517/4885 |
| US-10174025-B2 | Pyrazole derivative manufacturing method | CYP3A5, CYP3A7, CYP3A4 | ADORA2A 2224/4885ADORA1 1954/4885IRAK4 858/4885 |
| US-20180099964-A1 | PYRAZOLE DERIVATIVE MANUFACTURING METHOD | CYP3A5, CYP3A7, CYP3A4 | ADORA2A 2224/4885ADORA1 1954/4885IRAK4 858/4885 |
| US-20190071441-A1 | PYRAZOLE DERIVATIVE MANUFACTURING METHOD | CYP3A5, CYP3A7, CYP3A4 | ADORA2A 2224/4885ADORA1 1954/4885IRAK4 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.